Access to Medicines
More about the ongoing talks at WTO to increase access to essential medicines, especially in developing countries.
Please find all related articles below.
The new ’VulnerABLE’ Project aims to increase our understanding of how best to improve the health of people who are living in vulnerable and isolated situations in the European Union. It began in early 2016 and will continue for two years, with EPHA as a collaborating partner.
By Sascha Marschang, Policy Manager for Health Systems, EPHA
The new ’VulnerABLE’ Project aims to increase our understanding of how best to improve the health of people who are living in (...)
children and adolescents
Ageing and Older People
Universal Health Care (UHC)
On 10 February 2016, European Ministers of Health and Agriculture were invited by the Netherlands Presidency of the EU Council to a Ministerial Conference on Antimicrobial Resistance (AMR) in Amsterdam. The Ministers discussed the scale and urgency of the crisis facing health systems around the world. For the fight against AMR to be successful, the most important element is coordinated international action, not least at the EU level. Dutch Minister of Agriculture Martijn van Dam made it (...)
In February, trade negotiators from the EU and the US met in Brussels for the twelfth round of negotiations on the Transatlantic Trade and Investment Partnership (TTIP) - behind closed doors. Amongst other things, they discussed an EU proposal on regulatory cooperation on Generic Medicines. The negotations could have dramatic impacts on affordability and accessibility of medicines in Europe, depending on whether the negotiators prioritise public health goals. Is the negotiators’ main (...)
Brussels, 27 January 2016 - With regard to the upcoming vote on the proposed ’Trade Secrets Directive’ in the Legal Affairs Committee of the European Parliament (JURI) scheduled for 28 January 2016, a coalition of NGOs issued a joint statement colling for the rejection of the directive as legal uncertainty endangers access to information. EPHA joined the call as the concept of ’trade secrets’ could harm public health and can undermine public access to data on the (...)
EPHA’s new report on Access to Childhood Vaccination emphasises the importance of ensuring free and equal access to immunisation for all children in Europe no matter their legal or economic status. Issues pertaining to access to vaccinations were also stressed at the first Science-Policy Flu Summit organised by EPHA members the European Scientific Working Group on Influenza (ESWI).
Focus on Childhood Vaccination
The report discusses the barriers to parents being fully informed and (...)
Antimicrobial Resistance (AMR) is a global health threat of unprecented scale and urgency. During the first World Antibiotic Awareness Week (WAAW) from 16-22 November 2015, which encompassed the 8th European Antibiotic Awareness Day (EAAD), emphasis was placed on the global nature of the emergency that requires all institutions and actors to join forces. At the launch event in Brussels, the European Commission, ECDC and WHO sent a clear signal that only effective collaboration can tackle (...)
Since the economic crisis, policy changes across Europe appear to be moving away from universal health systems with broad coverage to systems where sections of the population are excluded from the scope of publicly available services. A new EPHA report presents and analyses these trends from across Europe and makes a contrast between the evidence that inclusive health, social, welfare and employment policies being beneficial to the economy with recent changes and health outcomes.
As well (...)
An important chapter of the Transatlantic Trade and Investment Partnership (TTIP) trade negotiations between the EU and US deals with ’Regulatory Cooperation’. Whilst it may sound dull and harmless it poses and extremely serious threat to national governments’ right to regulate, for example to protect public health, consumer rights, workers or the environment. EPHA emphasises the need to defend governments’ and the EU’s right to legislate and set policies to (...)
On 15 July 2015 EPHA and Wemos hosted an event in the Members’ Salon at the European Parliament to highlight the issue of added therapeutic value (ATV) in medicines.
Several studies carried out at EU member state level indicate that the majority of medicines authorised for use have little-to-no ATV in comparison with existing treatments. This means that public money is being spent on new, costly medicines which have limited ATV, whilst also using up resources which might otherwise be (...)
Supplying poor and developing countries with medicines at sustainable, reduced prices is one of the most important tools in the fight against major diseases, especially the “Big Three”, namely HIV, TB and malaria. After more than a decade since the Council Regulation (EC) 953/2003 came into force, to avoid trade diversion into the European Union of certain key medicines, stakeholders came together to discuss the overall impact of the Regulation at a workshop on 15 July 2015, (...)